Direct Healthcare Professional Communication on the significant update to premedication administration timing for patients on subcutaneous ocrelizumab in Northern Ireland (NI) to align with the UK Summary of Product Characteristics (SmPC) from 1st January 2025, as a result of the Windsor Framework Agreement.

This information is applicable to Healthcare Professionals based in Northern Ireland only.